ADAPTIMMUNE THERAPEUTICS-ADR (ADAP)
US00653A1079 - ADR
ChartMill assigns a Buy % Consensus number of 77% to ADAP. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 3.57. This target is 213.16% above the current price.
ADAP was analyzed by 13 analysts. The buy percentage consensus is at 77. So analysts seem to be have mildly positive about ADAP.
In the previous month the buy percentage consensus was at a similar level.
ADAP was analyzed by 13 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2023-08-10 | EF Hutton | Reiterate | Buy -> Buy |
| 2023-08-10 | Barclays | Maintains | Underweight -> Underweight |
| 2023-06-05 | EF Hutton | Reiterate | Buy -> Buy |
| 2023-06-02 | EF Hutton | Reiterate | Buy |
| 2023-05-26 | EF Hutton | Reiterate | Buy |
| 2023-04-17 | EF Hutton | Reiterate | Buy |
| 2023-04-11 | EF Hutton | Reiterate | Buy |
| 2023-03-06 | EF Hutton | Reiterate | Buy |
| 2023-01-05 | EF Hutton | Initiate | Buy |
| 2023-01-03 | Guggenheim | Upgrade | Neutral -> Buy |
| 2022-11-14 | Wells Fargo | Maintains | Equal-Weight |
| 2022-11-09 | Mizuho | Upgrade | Neutral -> Buy |
| 2022-10-04 | Wells Fargo | Maintains | Equal-Weight |
| 2022-05-09 | SVB Leerink | Maintains | Market Perform |
| 2021-09-22 | Wells Fargo | Maintains | Equal-Weight |
| 2021-09-13 | SVB Leerink | Maintains | Market Perform |
| 2021-09-07 | SVB Leerink | Maintains | Market Perform |
| 2021-08-10 | SVB Leerink | Maintains | Market Perform |
| 2021-05-28 | Barclays | Initiate | Underweight |